Trial Profile

A Phase 2 Study of Mivavotinib in Biomarker-Defined Subgroups of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mivavotinib (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Calithera Biosciences

Most Recent Events

31 Mar 2023 Status changed from recruiting to discontinued.
14 Nov 2022 According to a Calithera Biosciences media release, details of the study design were presented in a trial-in-progress poster at the Pan Pacific Lymphoma Conference in July, 2022.
13 Jul 2022 According to a Calithera Biosciences media release, data from this study will be presented at the 2022 Pan Pacific Lymphoma Conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com